You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

https://doi.org/10.1136/jitc-2020-001235corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Neelapu SS, Adkins S, Ansell SM, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 2020;8:e001235. doi: 10.1136/jitc-2020-001235

    In the Panel recommendations for Burkitt’s lymphoma, the statement ‘Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+doxorubicin+methotrexate / ifosfamide+etoposide+cytarabine (R-CODOXM/IVAC), DA-R-EPOCH, rituximab+ German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+doxorubicin+dexamethasone+pegfilgrastim alternating with rituximab+methotrexate+cytarabine (R-HyperCAD)’ has been corrected as below to add vincristine, omit pegfilgrastim and correct the acronym from ‘R-HyperCAD’ to ‘R-HyperCVAD’:

    ‘Options include rituximab+Lymphome Malins de Burkitt (R-LMB), rituximab+cyclophosphamide+doxorubicin+methotrexate / ifosfamide +etoposide+cytarabine (R-CODOXM/IVAC), DA-R-EPOCH, rituximab+German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Protocol (R-GMALL), and rituximab+cyclophosphamide+vincristine+doxorubicin+dexamethasone alternating with rituximab+methotrexate+cytarabine (R-HyperCVAD).’